Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

por Laliberté, François, Raut, Monika, Yang, Xiaoqin, Germain, Guillaume, Nahar, Akash, Desai, Kaushal D., MacKnight, Sean D., Sen, Shuvayu S., Duh, Mei Sheng
Publicado 2020

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to An...

por Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Nahar, Akash, Herrera, Alex F.
Publicado 2022

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma...

por Borchmann, Peter, Johnson, Nathalie A., Lavie, David, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash, Timmerman, John
Publicado 2022

P089: Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-...

por Vinti, Luciana, Daw, Stephen, Alvarez, Constantino Sabado, Fagioli, Franca, Beishuizen, Auke, Michel, Gerard, Moleti, Maria Luisa, Cepelova, Michaela, Thorwarth, Anne, Rigaud, Charlotte, De Sabando, Diego Plaza Lopez, Parker, Judith Landman, Zhu, Ying, Pillai, Pallavi, Nahar, Akash, Mauz-Koerholz, Christine
Publicado 2022

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

por Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S. R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John
Publicado 2022

S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIG...

por Gyurkocza, Boglarka, Seropian, Stuart, Choe, Hannah, Litzow, Mark, Abboud, Camille, Koshy, Nebu, Stiff, Patrick, Tomlinson, Benjamin, Abhyankar, Sunil, Foran, James M, Hari, Parameswaran, Chen, George, Al-Kadhimi, Zaid, Kebriaei, Partow, Sabloff, Mitchell, Orozco, Johnnie, Jamieson, Katarzyna, Silverman, Margarida, Van Besien, Koen, Schuster, Michael, Law, Arjun, Abedin, Sameem, Larkin, Karilyn, Rowley, Scott, Munshi, Pashna, Cook, Rachel, Mayer, Sebastian, Levy, Moshe Yair, Lazarus, Hillard, Sandmaier, Brenda, Reddy, Vijay, Spross, Jennifer, Mcnamara, Kathleen, Haeuber, Elaina, Vusirikala, Madhuri, Nahar, Akash, Pagel, John, Giralt, Sergio, Desai, Avinash, Nath, Rajneesh
Publicado 2023